Advice
Relevance to NICE guidance programmes
Relevance to NICE guidance programmes
The off-label use of domperidone is not appropriate for referral for a NICE technology appraisal and is not currently planned into any other work programme.
Domperidone is mentioned very briefly in 2 NICE clinical guidelines, neither specifically relating to its use in promoting tolerance of enteral feeds in children and young people:
-
Dyspepsia: management of dyspepsia in adults in primary care (NICE clinical guideline 17) states evidence is sparse about using domperidone as a prokinetic in the treatment of dyspepsia.
-
Type 2 diabetes – newer agents (partial update of CG66) (NICE clinical guideline 87) says to consider a trial of metoclopramide, domperidone or erythromycin for an adult with gastroparesis. This is in relation to the secondary effects of type 2 diabetes.
A NICE clinical guideline on gastro-oesophageal reflux in children and young people is in development. It is expected to be published in October 2014 and will include the effectiveness of prokinetic agents for gastro-oesophageal reflux.